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Mechanisms of amphetamine action illuminated
through optical monitoring of dopamine synaptic
vesicles in Drosophila brain
Zachary Freyberg1,2,*, Mark S. Sonders1,2,3,*, Jenny I. Aguilar1,2, Takato Hiranita4, Caline S. Karam1,2,
Jorge Flores5, Andrea B. Pizzo1,2, Yuchao Zhang1,2, Zachary J. Farino1,2, Audrey Chen6, Ciara A. Martin7,
Theresa A. Kopajtic4, Hao Fei6, Gang Hu8, Yi-Ying Lin9, Eugene V. Mosharov3, Brian D. McCabe10,11,12,
Robin Freyberg13, Kandatege Wimalasena14, Ling-Wei Hsin9, Dalibor Sames8, David E. Krantz6,
Jonathan L. Katz4, David Sulzer1,2,3,15 & Jonathan A. Javitch1,2,15
Amphetamines elevate extracellular dopamine, but the underlying mechanisms remain
uncertain. Here we show in rodents that acute pharmacological inhibition of the vesicular
monoamine transporter (VMAT) blocks amphetamine-induced locomotion and self-
administration without impacting cocaine-induced behaviours. To study VMAT’s role in
mediating amphetamine action in dopamine neurons, we have used novel genetic,
pharmacological and optical approaches in Drosophila melanogaster. In an ex vivo whole-brain
preparation, fluorescent reporters of vesicular cargo and of vesicular pH reveal
that amphetamine redistributes vesicle contents and diminishes the vesicle pH-gradient
responsible for dopamine uptake and retention. This amphetamine-induced deacidification
requires VMAT function and results from net Hþ antiport by VMATout of the vesicle lumen
coupled to inward amphetamine transport. Amphetamine-induced vesicle deacidification also
requires functional dopamine transporter (DAT) at the plasma membrane. Thus, we find that
at pharmacologically relevant concentrations, amphetamines must be actively transported by
DAT and VMAT in tandem to produce psychostimulant effects.
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P
rescribed and illicit amphetamines, including amphetamine
and methamphetamine derivatives, are some of the most
widely used and abused drugs: Total prescriptions number
over 15 million yearly in the US, with B56 million users
globally1. Amphetamines’ psychostimulant effects are generally
thought to result from increased extracellular dopamine mediated
by efflux of cytoplasmic dopamine through the dopamine
transporter (DAT)2. How amphetamines mobilize dopamine
from vesicles to the cytoplasm for subsequent efflux is less clear.
Dopamine is synthesized in the cytosol and concentrated into
synaptic vesicles B105-fold (B0.1M intraluminal dopamine)
relative to cytoplasmic dopamine (B1 mM) by the vesicular
monoamine transporter (VMAT)3–5. Whether amphetamines
also act directly on VMAT to redistribute dopamine from vesicles
into the cytoplasm has been debated, and numerous mechanisms
have been proposed6.
Amphetamines interact with VMAT in vitro, leading some
investigators to conclude that they act as non-substrate inhibitors
that elevate cytoplasmic dopamine by simply blocking its
accumulation into vesicles and thus making more available for
efflux7. Others have inferred that amphetamines are substrates of
VMAT that drive carrier-mediated exchange of vesicular
monoamines into the cytoplasm8,9. A third proposed
mechanism is that amphetamines deplete synaptic vesicle
dopamine stores through mechanisms akin to lipophilic weak
bases and protonophores2,10, which degrade the vesicular pH
gradient (DpH). This DpH, generated by the vacuolar Hþ -
ATPase (V-ATPase), not only drives loading of monoamines into
the vesicle lumen by VMAT, but also promotes intravesicular
retention of monoamines through their protonation11.
Amphetamines are weak bases (pKa 8.8–9.9) and have been
proposed to decrease the vesicular DpH by buffering luminal free
protons, thereby depleting vesicles of stored dopamine and
indirectly blocking substrate import. This is the mechanism of
action for weak bases such as chloroquine, which is lipophilic
enough to diffuse across lipid bilayers (LogP¼ 4.72)11–14.
Although amphetamines are less lipophilic (for example, LogP
of amphetamine¼ 1.41)15, they have been hypothesized both to
enter vesicles by diffusion as well as by VMAT-mediated
transport2. Evidence for these diverse mechanisms has come in
large part from in vitro studies of isolated vesicles, cells and brain
slices, but the actual relevance of these proposed mechanisms to
amphetamines’ in vivo actions has not been ascertained.
Earlier work by Dwoskin and colleagues showed that
tetrabenazine and lobeline analogues, which are inhibitors
of the neuronal VMAT isoform, VMAT2, blocked
methamphetamine’s behavioural action in rodents16,17. While
these results suggested that VMAT is instrumental in mediating
methamphetamine’s effects, several of these compounds have
modest selectivity for VMAT2 and also inhibit DAT. To address
this, we developed a new VMAT blocker, (þ )-CYY477, with
improved selectivity and show that acute VMAT inhibition in
rodents blocks locomotor and self-administration behaviours
stimulated by amphetamines without affecting those induced by
cocaine. This selective antagonism indicates that VMAT function
is required for the acute actions of amphetamines to release
dopamine from intraluminal stores.
To elucidate how amphetamines act on synaptic vesicles to
release dopamine into the cytoplasm, we developed an experi-
mental system in Drosophila melanogaster using a functionally
viable ex vivo brain preparation16. Actions of amphetamines were
studied in this whole-brain preparation using small synthetic
and genetically-encoded fluorescent reporters visualized by
multiphoton microscopy. We used the second-generation
fluorescent false neurotransmitter FFN206 (ref. 17) in
combination with genetic manipulations to monitor in real time
the dynamics of dopaminergic vesicle cargo in whole fly brains.
To examine the effects of amphetamines on vesicle pH, we
expressed the synaptic vesicle pH biosensor, dVMAT-pHluorin18,
in dopaminergic neurons, which allowed us to monitor real-time
changes in synaptic vesicle pH in whole living brain.
Our findings in flies demonstrate that at pharmacologically
relevant concentrations, amphetamines, as well as other VMAT
substrates, must be transported by VMAT to diminish vesicular
DpH and redistribute vesicular contents. Our data suggest
that VMAT-mediated substrate-coupled Hþ antiport provides
the critical mechanism for amphetamine-induced vesicular
deacidification.
Results
VMAT mediates acute amphetamine-induced rodent behaviours.
To validate VMAT2’s role in acute behavioural actions of
amphetamines in rodents, we developed (þ )-CYY477, a novel
derivative of dihydrotetrabenazine that retains high VMAT2
affinity but has better selectivity (Supplementary Note 1). (þ )-
CYY477 potently inhibited dopamine uptake by rat VMAT2
expressed in cultured cells (half-maximal inhibitory concentration
(IC50)¼ 26nM; Supplementary Fig. 1a). (þ )-CYY477 also exhib-
ited good selectivity for vesicular over plasma membrane mono-
amine transporters. It inhibited binding to mammalian VMAT2
(Ki¼ 7.18±1.14 nM), but was inactive at DAT, the serotonin
transporter and the norepinephrine transporter (see
Supplementary Methods, Supplementary Table 1). Thus, given
(þ )-CYY477’s potency and selectivity for VMAT2, we used it to
examine effects of acute pharmacological inhibition of VMAT2 on
psychostimulant actions in both mice and rats (see Supplementary
Methods, Fig. 1, Supplementary Fig. 2). In these protocols, (þ )-
CYY477 was administered r5min preceding psychostimulant
treatments, allowing us to avoid potential confounds associated with
gene knockdown or chronic pharmacological depletion of mono-
amine stores. Acute (þ )-CYY477 pretreatment (0.3–10mgkg 1)
significantly diminished methamphetamine (3mgkg 1)-induced
hyperlocomotion in mice (Fig. 1a). In contrast, (þ )-CYY477 failed
to attenuate cocaine (20mgkg 1)-induced hyperlocomotion
(Fig. 1b). Preservation of the locomotor response to cocaine indi-
cates that vesicular dopamine stores were functionally intact using
these (þ )-CYY477 doses. Notably, the acute (þ )-CYY477 doses
used in this mouse hyperlocomotion assay were substantially lower
than those that produced catalepsy (Supplementary Fig. 1b,
Supplementary Discussion). Furthermore, in psychostimulant self-
administration assays performed in rats, acute (þ )-CYY477 pre-
treatment inhibited self-administration of both methamphetamine
and amphetamine in a dose-dependent manner (Fig. 1c,d), whereas
cocaine self-administration was again unaffected (Fig. 1e;
Supplementary Discussion). Both cocaine and amphetamines are
expected to produce locomotor and self-administration behaviours
through the common step of elevating extracellular dopamine
levels19. However, that (þ )-CYY477 selectively antagonized
amphetamine and methamphetamine-induced behaviours but not
those of cocaine, clearly illustrates that VMAT2 plays a critical role
in the acute actions of amphetamines but not those of cocaine.
dVMAT is essential for amphetamine behaviour in Drosophila.
Building on these findings in rodents, we established a novel
experimental system in D. melanogaster to dissect mechanisms
of monoaminergic neurotransmission in vivo. The genetic
tractability of Drosophila permits targeted manipulation of gene
expression to determine contributions of individual genes to
amphetamine’s actions and the neuronal pathways in which
they function. Using a behavioural assay of amphetamine-
induced hyperlocomotion20,21, we first examined whether
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the sole Drosophila VMAT isoform, dVMAT, is required for
amphetamine to produce its behavioural effects in larvae.
Vehicle-fed dVMAT null mutants had significantly diminished
baseline crawling velocity relative to wildtype (WT) controls
(approximately sixfold decrease, Po0.001; Fig. 2a). The
amphetamine-induced increase in crawling velocity was
approximately fivefold greater in WT than in dVMAT
null mutants, demonstrating that VMAT is essential for
amphetamine-induced hyperlocomotion.
To identify the presynaptic neuronal populations that mediate
dVMAT’s contribution to amphetamine-induced locomotion,
we restricted dVMAT expression to different monoaminergic
populations. We used the tyrosine hydroxylase (TH)-GAL4
expression driver22 in the dVMAT null23 background to restore
expression of dVMAT selectively in dopamine neurons
(‘TH Rescue’; see Fig. 2b schematic). These larvae had a
baseline crawling velocity (0.14mm s 1) similar to dVMAT
null larvae (0.13mm s 1; P40.05 difference) (Fig. 2a).
Nonetheless, feeding amphetamine to TH Rescue larvae greatly
increased their crawling velocity (D¼ 0.12mm s 1; Po0.001),
producing an increase similar to WT larvae (D¼ 0.16mm s 1).
dVMAT was also selectively expressed in octopamine (OA)
and tyramine (TA) neuron populations using the tyrosine
decarboxylase 2 (Tdc2)-GAL4 expression driver24 (Tdc Rescue,
Fig. 2b) in the dVMAT null background. In contrast to TH
Rescue animals, Tdc Rescue larvae exhibited no significant
amphetamine-stimulated hyperlocomotion (D¼ 0.01mm s 1,
P40.05) even though their rates of basal locomotion
(0.73mm s 1) were comparable to WT (0.83mm s 1; P40.05
difference). Thus, dVMAT expression specifically in dopamine
neurons plays a critical role in mediating amphetamine-
stimulated behaviour in flies, consistent with voluminous data
that dopamine is the primary mediator of amphetamine’s
psychomotor stimulatory action in mammals2,25.
FFN206 labels monoaminergic nerve terminals in whole brain.
To analyse the mechanisms of monoamine loading and release
from synaptic vesicles, we used an ex vivo whole fly brain
preparation to optically monitor monoaminergic vesicle
content by multiphoton microscopy. We utilized FFN206, which
was designed as a fluorescent VMAT2 substrate and has an
apparent transport affinity (Km¼ 1.16±0.10 mM)17 similar to
that of dopamine (Km¼ 0.92±0.05 mM) (ref. 8). In WT brains
continuously bathed in FFN206, we observed a dense pattern of
B1 mm fluorescent puncta that varied through the neuropil,
consistent with the accumulation of the probe into
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Figure 1 | Acute (þ )-CYY477 pretreatment selectively antagonizes behavioural effects of amphetamine and methamphetamine in rodents.
(a) Methamphetamine stimulation of horizontal locomotion in mice. Left panel: methamphetamine increased activity in a dose-related manner with
maximal elevation at a 3mg kg 1 i.p. dose (open points). ‘V’ (vehicle) indicates locomotor activity rate after two saline vehicle injections (closed point).
Right panel: locomotion stimulated by 3mg kg 1 methamphetamine (solid bar) was antagonized by acute preinjection of (þ )-CYY477 in a
dose-dependent manner (open triangles) (b) Cocaine stimulation of horizontal locomotion in mice. Left panel: dose-related increases in activity
(open squares, ‘V’ two saline injections). Right panel: Locomotion stimulated by 20mg kg 1 cocaine (solid bar) was unaffected by acute preinjection of
(þ )-CYY477 up to 10mg/kg doses (open diamonds). (a,b) all drug doses were administered i.p. Mean and s.e.m. from six mice per group. (c–e) Selective
antagonism by (þ )-CYY477 of self-administration of psychostimulants in rats. Acute (þ )-CYY477 pretreatment dose-dependently attenuated
self-administration of both amphetamine (c) (Po0.001) and methamphetamine (d) (Po0.001). For self-administration rates (0.10mg kg 1 per injection
of either amphetamine): (þ )-CYY477 0.001mg/kg (tZ2.33; Pr0.14), 0.0032mg kg 1 (tZ3.87; Pr0.002), 0.01mg kg 1 (tZ9.03; Po0.001).
Two-way repeated measure ANOVAs also indicate significant effects on amphetamine doses (F(4,60)¼ 21.8, Po0.001) and methamphetamine doses
(F(4,60)¼ 23.6, Po0.001). (e) Cocaine self-administration was not diminished by acute (þ )-CYY477 pretreatment at any dose tested. (c–e) Ordinates:
responses per s; abscissae: psychostimulant dose (mg kg 1 per injection, i.v.). Each point represents the mean±s.e.m. of response rates on the active
lever in six rats per group; EXT: extinction (no injection). ‘0mg/kg’ of (þ )-CYY477 indicates vehicle (saline-only) pretreatment. i.p., intraperitonially; i.v.,
intravenous.
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Figure 2 | dVMAT expression in presynaptic dopamine neurons mediates amphetamine-induced Drosophila larval hyperlocomotion. (a) Wildtype
(WT) wCS10 larvae fed amphetamine (60mM) exhibited hyperlocomotion compared with vehicle (yeast alone; D mean velocity¼0.16mms 1,
P¼0.002, vehicle: N¼ 20; amphetamine: N¼ 21). dVMAT null larvae exhibited significantly diminished baseline crawling velocity relative to the WT
controls (5.3-fold difference, Po0.001) with a much smaller increase in locomotion velocity to amphetamine (D¼0.03mms 1, t(95)¼4.36, Po0.001;
vehicle: N¼ 51; amphetamine: N¼46). dVMAT null larvae with selective rescue of dVMAT expression in presynaptic dopamine neurons (TH Rescue)
exhibited blunted basal locomotion, similar to the dVMATnull, but displayed a robust amphetamine response (D¼0.12mms 1, Po0.001; vehicle: N¼44;
amphetamine: N¼49). Selective dVMATrescue in OA/TA neurons (Tdc Rescue) restored basal locomotion to WT levels but not amphetamine-stimulated
hyperlocomotion (D¼0.01mms 1, P40.05; N¼44). See Supplementary Fig. 3 showing that expression drivers alone had no effect. Every condition
represents the mean±s.e.m. with all experiments conducted on Z2 separate occasions. (b) Schematic illustration of monoamine neurotransmitter-
containing vesicles in flies of different genetic backgrounds. dVMAT expression (indicated in red) confers the ability to accumulate dopamine, OA, TA,
serotonin (5-HT) and histamine (HA) in synaptic vesicles but is absent in the dVMATnull genetic background. TH Rescue or Tdc Rescue selectively restores
dVMAT function in dopamine or OA/TA neurons, respectively.
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Figure 3 | FFN206 accumulation is dependent on dVMAT and selectively labels presynaptic DA nerve terminals in adult fly TH Rescue brain.
(a) Multiphoton microscopy of FFN206-loaded adult WT brain revealed extensive presynaptic monoaminergic nerve terminal labelling in the central brain
neuropil, accumulating in punctao1mm diameter. Labelled regions include the suboesophageal ganglion (SOG), antennal lobe (AL) and the protocerebrum
(Proto). (b) Absence of dVMATexpression in brains of dVMAT null mutants abolished virtually all neuropil FFN206 labelling. Residual signal was primarily
autofluorescence from tracheal structures (triangle)74 as well as some variable staining outside the neuropil. (c) Schematic illustration of the expected
monoamine content of FFN206-loaded vesicles (blue fill) in WT, dVMATnull and TH Rescue brains. (d) FFN206 selectively labelled presynaptic dopamine
nerve terminals in adult TH Rescue brain with particular enrichment in MB-MV1 neurons (arrow and white box). (e) Single-plane image of MB-MV1 as
labelled by FFN206 in a TH Rescue brain. (f) Reserpine pretreatment of an adult TH Rescue brain prevented FFN206 labelling, similar to dVMAT null brain
(b). (g) FFN206 labelling of adult TH Rescue brain was similarly blocked by pretreatment with (þ )-CYY477 (1mM, 20min, 25 C) (compare with f).
String-like structures in e–g are autofluorescent trachea. Comparable results were obtained from NZ3 independent experiments. Images are from
projected Z series of coronal sections acquired with similar settings and of comparable depth; all scale bars are 25mm, except for e (Scale bar, 5 mm).
lex¼ 820nm, lem¼460/50nm FWHM.
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monoaminergic nerve terminals (Fig. 3a). Labelling was observed
in the antennal lobes, suboesophageal ganglion and the
protocerebrum (Fig. 3a). Steady-state labelling with 300 nM
FFN206 yielded a high signal to background ratio of 60.2±4.7.
Neuropil labelling was dVMAT-specific as it was virtually absent
from dVMAT null mutant flies (Fig. 3b), establishing FFN206 as
an excellent tool for labelling monoaminergic vesicles in the fly.
Selective labelling of dopamine terminals with FFN206. Since
FFN206 labels multiple monoaminergic populations that express
dVMAT in WT brain, we used the TH Rescue genetic back-
ground to drive dVMAT expression selectively in dopamine
neurons (Fig. 3c schematic). We observed strong FFN206 label-
ling of TH Rescue brains in a dense field of dopamine nerve
terminals belonging to the MB-MV1 neurons that project to the
mushroom bodies and have recently been implicated in associa-
tive learning26,27 (Fig. 3d,e). FFN206 also labelled presynaptic
dopamine terminals in the suboesophageal ganglion, antennal
lobes, mushroom bodies (Fig. 3d) and the central complex (data
not shown). Pretreatment with the VMAT inhibitors reserpine
(1 mM, Fig. 3f) or (þ )-CYY477 (1 mM, Fig. 3g), completely
blocked neuropil labelling by subsequent application of FFN206
in TH Rescue brains. These data are consistent with the necessary
role of VMAT for FFN206 labelling, also shown in the genetic
dVMAT null mutants (Fig. 3b). Therefore, by using FFN206 to
label TH Rescue brains, we can specifically image dopamine
terminals to examine the neurochemical mechanisms that
regulate the content of dopamine vesicles in response to both
exocytic and non-exocytic releasing stimuli.
To study the kinetics of stimulated release in presynaptic
dopamine nerve terminals, we first measured exocytic vesicle
release from FFN206-labelled dopamine terminals in TH Rescue
brains. KCl-induced depolarization led to pronounced FFN206
destaining from a stable baseline, despite continued FFN206
application during KCl treatment (Fig. 4a). Analysis of
destaining kinetics revealed a rapid monoexponential decay of
FFN206 signal in the MB-MV1 region (t1/2¼ 6.42±0.60 s,
R2¼ 0.85±0.04, Fig. 4a). The initial lag before destaining was
mainly attributable to the time needed for the KCl to reach the
imaging chamber and for solution exchange (Supplementary
Fig. 4). The destaining rate is comparable to the rate of
exocytic vesicular neurotransmitter release evoked by electrical
stimuli at the larval neuromuscular junction (t1/2¼ 4.49±0.61 s,
Supplementary Fig. 5), as well as that described previously using
other optical reporters of exocytic neurotransmitter release
both in fly neuromuscular junction and cultured vertebrate
neurons28,29. The sparse punctate staining resistant to KCl-
depolarization may be due to the heterogeneous release properties
of monoaminergic nerve terminals, as reported recently in mouse
brain slices30.
The lipophilic weak base chloroquine (100 mM) also caused
monoexponential destaining of FFN206 (t1/2¼ 26.57±3.73 s,
R2¼ 0.97±0.01) (Fig. 4b). Treatment with 1 mM amphetamine
likewise diminished FFN206 signal to levels comparable to
surrounding neuropil background (Fig. 4c) (t1/2¼ 66.60±17.08 s,
R2¼ 0.99±0.004). Notably, amphetamine-induced FFN206
destaining was not blocked by inhibiting voltage-gated Naþ
channels (tetrodotoxin, 500 nM) and nicotinic cholinergic
receptors (tubocurarine, 10mM; data not shown), suggesting that
the FFN redistribution was due to local action at the terminals
and not to circuit-wide excitation. Thus, FFN206 has permitted
us to monitor for the first time the dynamics of neurotransmitter
content within intact dopaminergic vesicles in an ex vivo whole-
brain preparation. We hypothesized that KCl, chloroquine and
amphetamine operate through distinct mechanisms, and explored
these mechanisms with the recently developed in vivo pH sensor
dVMAT-pHluorin18, as described below.
Characterization of dVMAT-pHluorin, a vesicular pH
biosensor. We characterized a genetically encoded fluorescent
reporter of intraluminal pH to examine changes in monoamine
vesicle pH. This biosensor (termed dVMAT-pHluorin) was
created by inserting pHluorin, a superecliptic, pH-sensitive
GFP31, into the dVMAT polypeptide’s first luminal loop18.
dVMAT-pHluorin was trafficked appropriately to synaptic
vesicles as indicated by co-localization with synaptotagmin 1
(syt1), an established vesicle marker (Supplementary Fig. 5a–c).
When driven by the TH promoter, dVMAT-pHluorin’s
expression pattern in presynaptic dopamine nerve terminals
(Supplementary Fig. 5g) appeared identical to FFN206’s punctate
staining pattern in TH Rescue brain (compare with Fig. 3d).
dVMAT-pHluorin’s fluorescence intensity was dependent on pH,
with a high signal to noise ratio (162.6±27.2) and broad dynamic
range (Supplementary Fig. 6). Both electrical stimulation
(Supplementary Fig. 5d–f) and KCl-induced depolarization
significantly enhanced dVMAT-pHluorin’s fluorescence
intensity by shifting the pH sensor moiety from the acidic
vesicle environment to the neutral extracellular space on vesicle
exocytosis (Supplementary Fig. 6a). Under basal conditions, the
percentage of dVMAT-pHluorin on the cell surface in our ex vivo
whole fly brain preparation (14.5%±2.5%) is consistent with that
described previously for vesicular pH biosensors heterologously
expressed in cultured cells31–33. dVMAT-pHluorin’s pKa
(7.5±0.2; Supplementary Fig. 6b) was similar to those of
synaptopHluorin (7.1–7.3) and superecliptic pHluorin (7.2)31,34.
Furthermore, dVMAT-pHluorin is a functional transporter as
expression of the UAS-dVMAT-pHluorin transgene using the
Tdc2-GAL4 expression driver in dVMAT null background flies
rescued basal locomotion to 71% of WT levels (Po0.001)
(Supplementary Fig. 3b).
Amphetamine needs DAT and VMAT to alkalize dopamine
vesicles. We expressed the dVMAT-pHluorin biosensor in
presynaptic dopamine nerve terminals to directly monitor
amphetamine-induced pH changes in dopamine synaptic vesicles
in a whole brain for the first time. As a standard for comparison,
we used chloroquine (100 mM) to disrupt the vesicular Hþ
gradient and thus to alkalize the lumen relative to the acidic
starting pH. Amphetamine (1 mM) also caused significant
concentration-dependent alkalization, that is, deacidification,
of the vesicle (F(3, 16)¼ 29.96, Po0.001; Fig. 5a,b). This
amphetamine-induced rise in vesicle pH was sustained during
continuous application of the drug by bath superfusion
(Supplementary Fig. 7a). Methamphetamine (10 mM) also caused
significant vesicular alkalization (F(3, 20)¼ 9.03, P¼ 0.001;
Supplementary Fig. 8a). In contrast, treatment with the psycho-
stimulant methylphenidate, a non-substrate DAT inhibitor21 that
is also a lipophilic weak base (calculated pKa¼ 9.5 with
LogD¼ 0.24, pH 7.4 (ref. 35)), did not lead to intraluminal
vesicular pH changes (P40.05) (Fig. 5c) even at 100mM,
a concentration far higher than that needed to block DAT36,37.
By expressing dVMAT-pHluorin in the Drosophila DAT
(dDAT) null fumin mutant background38, we were able to
examine the role of dDAT in transporting amphetamines into
cells by using vesicle alkalization as a readout. Specifically, we
asked whether passive diffusion of amphetamines across the
plasma membrane supplies sufficient intracellular amphetamine
to produce vesicular alkalization or whether it must be imported
by the concentrative transporter dDAT. We found that in the
absence of functional dDAT, amphetamine did not significantly
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10652 ARTICLE
NATURE COMMUNICATIONS | 7:10652 | DOI: 10.1038/ncomms10652 | www.nature.com/naturecommunications 5
raise vesicle pH even at concentrations up to 700-fold greater
than the 1mM concentration that caused significant vesicle
alkalization in the WT background (P40.05; Fig. 5d).
Methamphetamine-induced vesicle alkalization was also blocked
in the dDAT null mutant background (Supplementary Fig. 8b). In
contrast, subsequent treatment of the same dDAT null brains
with chloroquine (100 mM) still produced significant vesicle
alkalization (Fig. 5d, Supplementary Fig. 8b). This is consistent
with chloroquine’s ability to lipophilically diffuse across
membranes and also demonstrates that the synaptic vesicles in
dDAT null brains are capable of intraluminal alkalization.
Next, we used a pharmacological strategy to block dVMAT
to determine whether its function at the vesicle membrane
is necessary for amphetamine-induced vesicle alkalization.
Pretreatment with the inhibitor reserpine (1 mM; dVMAT
IC50¼ 258 nM (ref. 39)) prevented amphetamine- and
methamphetamine-induced vesicle alkalization (Fig. 5e,
Supplementary Fig. 8c), even with extended incubations
of increasing amphetamine concentrations (100 nM–10 mM;
Supplementary Fig. 7a). Similarly, the VMAT inhibitor
(þ )-CYY477 blocked amphetamine-induced synaptic vesicle
alkalization (Supplementary Fig. 9). In contrast, subsequent
alkalization by chloroquine in the same brains (Po0.001)
was unaffected by reserpine blockade of VMAT (Fig. 5e,
Supplementary Figs 7b and 8c), highlighting the ability of
chloroquine to diffuse across the vesicle membrane independently
of VMAT, just as it diffuses across the plasma membrane
independently of DAT (Fig. 5d).
Substrate-coupled Hþ antiport by VMAT alkalizes vesicles.
The experiments above clearly demonstrated that amphetamines
cause vesicle alkalization in dopamine terminals in an ex vivo
whole-brain preparation. At low micromolar concentrations of
amphetamines, this alkalization requires concentrative transpor-
ters at both the plasma membrane (DAT) and the synaptic vesicle
membrane (VMAT). Notably, VMAT functions by stoichiome-
trically exporting 2Hþ from the vesicle lumen for each cationic
monoamine substrate it imports40. We hypothesized that if
amphetamines are truly VMAT substrates, then their transport
should diminish the vesicular DpH through the substrate-coupled
Hþ antiport mechanism. We therefore tested whether proven
VMAT substrates also alkalize vesicles. The endogenous substrate
dopamine caused significant concentration-dependent vesicular
alkalization (F(5, 21)¼ 6.74, Po0.001; Fig. 6a), like amphetamine
and methamphetamine. Similarly, FFN206, which is also a
reserpine-sensitive VMAT substrate17 (Fig. 3), led to significant
vesicle alkalization at 10 mM (F(3,12)¼ 4.10, P¼ 0.032; Fig. 6b).
However, unlike amphetamine or methamphetamine, 10 mM
FFN206 still alkalized vesicles in presynaptic nerve terminals in
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Figure 4 | Destaining of FFN206 from dopamine terminals in TH Rescue brains. Fly brains were loaded to steady-state with FFN206 and treated
with KCl, chloroquine (CQ), or amphetamine in the continued presence of FFN206. Projected image stacks of the protocerebral neuropil before (left) and
after (center) treatments and kinetics of fluorescence decay in MB-MV1 region (right) from representative experiments. (a) KCl (40mM) depolarization
caused rapid FFN206 destaining in presynaptic dopamine nerve terminals. Fluorescence intensity is described by an initial plateau followed by a
monoexponential decay (black line; for n¼ 3 experiments, t1/2¼6.42±0.60 s, R2¼0.85) (b) Disrupting the synaptic vesicle pH gradient with chloroquine
(100mM) destained FFN206, and was best fit to an initial plateau followed by a monoexponential decay (black trace; for N¼4 experiments,
t1/2¼ 26.57±3.73 s, R2¼0.97). (c) Amphetamine (1mM) also caused FFN206 destaining, and was best fit to an initial plateau followed by a
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Fluorescence was normalized to levels attained following FFN206 loading to steady-state with 300 nM as measured in arbitrary units of fluorescence
intensity (AUI). Black arrows indicate initiation of drug addition (also containing 300nM FFN206) and the black circle in a represents the point at which
50% of drug reaches the imaging chamber. Scale bar, 25mm.
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the dDAT null mutant expressing dVMAT-pHluorin,
demonstrating that FFN206 requires dVMAT but not dDAT
for vesicle entry (Figs 3b,e,f and 6c). Notably, significant
vesicular pH changes were not observed with FFN206 at 1 mM
or at the 300 nM concentration we used as a monoamine tracer
(Fig. 6b).
That amphetamine and methamphetamine alkalize vesicles
with similar concentration dependence as established VMAT
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substrates, and even more importantly, that alkalization by
amphetamines can be blocked by VMAT inhibitors, together
support our hypothesis that substrate-coupled Hþ -antiport
accounts for the observed alkalization. Nevertheless, given that
amphetamine, methamphetamine, dopamine, and FFN206 are
weak bases, it is conceivable that if they were transported
in the neutral state, then the neutral species could bind protons
from the acidic vesicle lumen, eventually dissipating the vesicular
DpH. To determine whether substrate-coupled Hþ -antiport
by VMAT is sufficient to alkalize vesicles, it was necessary
to test a VMAT substrate that is not a weak base. Thus, we used
the known DAT and VMAT substrate, 1-methyl-4-phenylpyr-
idinium (MPPþ ), which cannot buffer luminal Hþ due to the
fixed positive charge of its methyl-pyridinium nitrogen41,42
(Fig. 7a).
MPPþ confirms the mechanism of vesicle alkalization by
VMAT. Bath application of 100mMMPPþ significantly alkalized
synaptic vesicles in presynaptic dopamine nerve terminals
(P¼ 0.028; Fig. 7b). In contrast, there was no significant
dVMAT-pHluorin brightening in presynaptic dopamine nerve
terminals following MPPþ treatment in either the dDAT null
mutant (Fig. 7d) or in WT brains pretreated with reserpine
(P40.05; Fig. 7e), consistent with MPPþ ’s dependence on both
dDAT and dVMAT. Moreover, MPPþ at the concentration that
produced dVMAT-pHluorin brightening (100 mM, Fig. 7b)
also destained FFN206 in dopamine terminals of TH Rescue
brains even in the continuous presence of FFN206. Destaining
showed monoexponential kinetics similar to amphetamine
(t1/2¼ 83.96±15.98 s, R2¼ 0.96±0.01; Fig. 7f), suggesting that,
like amphetamines, MPPþ can also cause redistribution of
dopaminergic vesicle contents through vesicle alkalization.
The relatively low potency of MPPþ compared with
amphetamine for vesicular alkalization and FFN206 destaining
is consistent with its low affinity for VMAT2 (Ki¼ 92±14 mM)
(ref. 43). Therefore, we also tested 30-OHMPPþ , a MPPþ
derivative with a higher affinity for VMAT2 (Ki¼ 2.4±0.1 mM)
(ref. 43). Indeed, 30-OHMPPþ caused significant vesicular
alkalization (Po0.001) at concentrations 10-fold lower (10 mM)
than MPPþ (compare Fig. 7b,c). Thus, despite the fact that they
are not weak bases, MPPþ and 30-OHMPPþ can still alkalize the
vesicle lumen like amphetamine, methamphetamine, dopamine,
and FFN206, which are weak bases. Critically, the property shared
by these diverse compounds is their ability to be transported by
VMAT. This finding indicates that transport-dependent Hþ
antiport by VMAT is sufficient to diminish intraluminal Hþ
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(F(3,16)¼ 137.93, Po0.001). (c) Escalating doses of 30-OHMPPþ significantly raised vesicle intraluminal pH (Po0.001) in a concentration-dependent
manner. 30-OHMPPþ was effective at a 10-fold lower concentration than MPPþ. (d) In dDAT null mutants, MPPþ (100mM) did not significantly raise
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fluorescence evoked by subsequent chloroquine (100mM) treatment in the same brains. (e) Mean change in fluorescence intensities±s.e.m. in the
MB-MV1 region from nZ3 experiments, normalized to initial fluorescence. (b–e) Drugs were sequentially applied to the brain preparation by bath
superfusion. Fluorescence was measured before treatment and after a 10-min drug equilibration period (25 C). (f) Fluorescence decay of MB-MV1 region
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concentration and alkalize the vesicle lumen without a need for
Hþ buffering.
This proposed antiport mechanism for substrate-induced
vesicular alkalization is not dependent on vesicle exocytosis. An
alternative explanation for dVMAT-pHluorin brightening could
be that vesicle exocytosis shifts the sensor from the acidic vesicle
lumen to the neutral extracellular milieu. To differentiate these
mechanisms, we again took advantage of MPPþ ’s properties as a
non-protonatable VMAT substrate that cannot buffer Hþ .
KCl or MPPþ were applied to brains expressing TH-driven
dVMAT-pHluorin as well as a genetically encoded Tetanus toxin
light chain (TeTxLC), a known blocker of exocytosis44. Given the
relatively fast kinetics of exocytosis, images were acquired at
higher frequency to detect rapid vesicular pH changes. Brief
pressure ejection of KCl led to a prolonged, intense pH change
(Fig. 8a) that was abrogated in flies expressing TeTxLC (Fig. 8b).
In contrast, brief application of MPPþ caused rapid, transient
intraluminal alkalization (Fig. 8c) that was not affected by
TeTxLC expression (Fig. 8d). We also used the same genetic
background of TeTxLC co-expression with dVMAT-pHluorin to
construct a vesicle intraluminal pH calibration curve using a
cocktail of ionophores across a broad pH range (see Methods);
the TeTxLC was required to avoid the potential confound of
vesicle exocytosis during calibration. By interpolating from this
curve, we determined that the mean peak change in fluorescence
intensity induced by transient application of MPPþ in these
TeTxLC experiments (DF/F¼ 0.31±0.07) corresponded to a 0.4
pH unit change from the baseline pH of B5.8 (95% confidence
interval: 5.48–6.08) (Supplementary Fig. 6c). These results
confirmed that MPPþ changes vesicle pH by a mechanism
independent of both exocytosis and Hþ buffering but dependent
on VMAT. Taken together, our results point to the intrinsic
substrate:Hþ antiport function of VMAT as the mechanism by
which amphetamines, or, more generally, any known VMAT
substrate, can elevate the pH within intact synaptic vesicles if it is
present in the cytoplasm at an adequate concentration.
Discussion
Although there is consensus that amphetamines produce
behavioural effects by raising extracellular dopamine levels,
diverse and often contradictory inferences have been drawn to
explain the molecular basis of this effect. In order to reveal
amphetamine’s actions at the synaptic vesicle level, we have
combined a number of novel, complementary genetic, optical and
pharmacological approaches to address these questions.
In both locomotor and self-administration behavioural
paradigms in rodents, acute preadministration of the novel
VMAT2 inhibitor (þ )-CYY477 abolished the effects of
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Figure 8 | MPPþ -induced dopamine synaptic vesicle alkalization in dopamine nerve terminals is reversible and independent of exocytosis.
(a) Pressure ejection of KCl (10 s, arrow) onto an ex vivo WTwhole fly brain preparation led to a delayed brightening of TH-driven dVMAT-pHluorin with a
slow decay. (b) The fluorescence response to KCl application (10 s, arrow) was abolished in fly brains expressing both dVMAT-pHluorin and tetanus toxin
light chain (TeTxLC), a known blocker of exocytosis, in dopamine nerve terminals. (c) MPPþ application (1 s, arrow) caused a more rapid dVMAT-pHluorin
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amphetamine and methamphetamine, indicating that VMAT2
function is obligatory for amphetamines to produce their acute
behavioural effects. These data are consistent with work by
Dwoskin and colleagues who have developed inhibitors of
methamphetamine behavioural actions using lobeline analogues.
During their structure-driven pre-clinical studies, this group
recognized that the drugs shared the common property of being
VMAT blockers45. Comparable behavioural effects against
methamphetamine were also observed with the VMAT2 blocker
tetrabenazine, but this drug shows only modest selectivity for
VMAT2 over DAT46. We tried to improve on the selectivity and
duration of action of tetrabenazine by synthesizing (þ )-CYY477,
a derivative of the high-affinity analogue dihydrotetrabenazine.
We found that (þ )-CYY477 indeed has high VMAT2 affinity
but negligible affinity for DAT (Supplementary Table 1).
Selectivity for VMAT2 over DAT is especially important for
discriminating between these transporters as sites of action for
amphetamines, which act at both. Taken together, our data
demonstrating (þ )-CYY477’s ability to block vesicular dopamine
uptake in vitro and to induce catalepsy at high doses in vivo
are consistent with other established VMAT inhibitors
like tetrabenazine and suggest that, like its parent compound,
(þ )-CYY477 is a potent and effective VMAT2 blocker.
The ability of (þ )-CYY477 and other VMAT inhibitors46–48
to block amphetamines’ behavioural actions rules out two widely
touted mechanisms for the in vivo action of these
psychostimulants at the doses we studied: (1) It has been
proposed that amphetamines elevate cytoplasmic dopamine by
blocking sequestration of endogenous dopamine into vesicles by
VMAT7, thus making more dopamine available for efflux by
DAT. If this were the case, then VMAT inhibitors would mimic
or enhance the behavioural effects of amphetamines. Instead,
we found that (þ )-CYY477 antagonized the effects of
amphetamines. (2) It has been proposed that, like cocaine,
amphetamines elevate extracellular dopamine by competing for
dopamine uptake by DAT49,50. If this were so at
pharmacologically relevant amphetamine concentrations, then
the selective VMAT2 inhibitor (þ )-CYY477, which has
negligible affinity for DAT, should not abolish the acute actions
of amphetamines at DAT. Instead, we found that (þ )-CYY477
antagonized the effects of amphetamines, although it did indeed
spare cocaine, consistent with cocaine’s competition with
dopamine at DAT. That cocaine-induced behaviours are
spared by (þ )-CYY477 also indicates that dopamine stores
and neurotransmission remain functionally intact after acute
pretreatment with the VMAT2 inhibitor.
The profound and selective antagonism of amphetamine-
induced behaviours by (þ )-CYY477 points to a critical role for
VMAT function in the acute actions of amphetamines upstream
of, and in addition to, their established action to facilitate efflux of
cytoplasmic dopamine through DAT.
We used a fly model system to elucidate the mechanism of
amphetamines’ actions at synaptic vesicles in vivo. We recently
introduced FFNs to enable rapid imaging of monoamine storage
and release dynamics in vertebrate brain slice30,51. A new FFN,
FFN206 (ref. 17) has proved to be an excellent marker of
monoaminergic nerve terminals in fly brain. To focus specifically
on dopaminergic terminals, we used flies genetically engineered
to express dVMAT only in TH-expressing dopamine neurons.
FFN206 labelling was reserpine-sensitive and was dissipated by
KCl-induced depolarization, consistent with the accumulation of
FFN206 in synaptic vesicles by dVMAT. Thus, this probe serves
as a sensitive and selective surrogate marker for dopamine
content in small synaptic and large dense core vesicles52.
Treatment with 1 mM amphetamine diminished FFN206 signal
to levels comparable to surrounding neuropil background. While
similar kinetics of amphetamine-induced destaining of previous
generation FFN molecules loaded into brain slices has been
shown51, this is the first report of amphetamine-induced
dopamine vesicle content release in whole brain.
Since vesicular pH plays an important role in storage and
release of vesicle contents, we used the recently developed
vesicular pH biosensor, dVMAT-pHluorin, as a tool to elucidate
amphetamines’ effects on intraluminal pH within intact vesicles
in our whole-brain preparation. This approach differs from
earlier uses of pHluorin biosensors to monitor vesicle dynamics
during exo- and endocytosis31,53. With dVMAT-pHluorin we
observed that a clinically relevant amphetamine concentration
(1 mM) alkalized dopamine vesicles within minutes in a
VMAT-dependent manner.
The concentrations of amphetamines that alkalize fly
brain dopaminergic vesicles and discharge their content are well
within the range of behaviourally active amphetamine or
methamphetamine levels found in human and rodent plasma
(B0.7 mM) (refs 54,55) and close to target plasma levels of
S(þ )amphetamine in therapeutic treatment of children with
attention deficit hyperactivity disorder (0.5–1.1 mM) (ref. 56) as
well as in chronic methamphetamine users (1–3 mM) (ref. 57).
Similarly, in rodents and non-human primates, behaviourally
active doses of amphetamines yield brain concentrations
(1–10 mM: striatal microdialysate)57–60 that are in the range of
those causing VMAT-dependent vesicular alkalization in fly
brain, although lower concentrations have also been reported50.
Lipophilic weak bases like chloroquine cause vesicle
alkalization and readily redistribute vesicle contents as we showed
in whole brain with FFN206. However, two lines of evidence
demonstrate that, at relevant concentrations, amphetamines do
not work by the same mechanisms as chloroquine. (1) Our data
show that disruption of DAT or VMAT function through
genetic or pharmacological manipulation profoundly reduced
amphetamine’s potency to alkalize the vesicle lumen. The
requirement for functional transporters at both the plasma
membrane and the vesicular membrane for amphetamine action
challenges the common assumption that lipophilic diffusion
alone can deliver enough amphetamine to vesicles to alkalize
vesicles, even at high micromolar concentrations of the drug.
By contrast, neither deletion of DAT nor blockade of VMAT
hindered chloroquine-induced alkalization. (2) That FFN206 is
accumulated in puncta in a VMAT-dependent manner gives
optical proof that mildly lipophilic compounds can be concen-
trated and that the vesicular membrane provides a sufficient
barrier to their egress. Since amphetamine (LogD¼  0.79 at pH
7.4 (ref. 15)) is less lipophilic than FFN206 (LogD¼  0.54 at pH
7.4 (ref. 17)), it should be even less capable of passive diffusion
into or out of vesicles. Altogether, these data provide the most
direct evidence to date that the amphetamines, like dopamine and
FFN206, are bona fide substrates of VMAT and not merely
inhibitors.
We next aimed to distinguish between two possible
mechanisms for this alkalization: (1) Alkalization of the acidic
lumen could occur by net export of 2Hþ via VMAT for
every amphetamine molecule transported into the vesicle
(substrate:2Hþ antiport)61 or (2) substrates including
amphetamines that are weak bases could buffer luminal Hþ
following their VMAT-dependent transport into the lumen if
their neutral, unprotonated species were transported2. Since
protonated amphetamine species (pKa¼ 9.9) outnumbers neutral
species by B300:1 in the cytosol at physiological pH, it seems
unlikely that sufficient neutral species would be transported
into the vesicle lumen to significantly buffer the acidic
environment15. Instead, our data are more consistent with the
cationic substrate:Hþ antiport mechanism, especially since
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the permanently charged VMAT substrates MPPþ and
30-OHMPPþ also alkalize vesicles even though they are not
weak bases. Thus, we infer that the Hþ antiport-driven process
of substrate translocation by VMAT is sufficient to account for
the vesicular alkalization produced not only by MPPþ and
30-OHMPPþ , which cannot be protonated, but also by the
VMAT substrates dopamine, amphetamine, methamphetamine
and FFN206, which have basic amino groups that are
predominantly protonated at physiological pH.
Measurements of synaptic vesicle pH are typically made in cells
or in isolated vesicles, and to our knowledge this study represents
the first attempt to measure the intraluminal pH of synaptic
vesicles in a whole living brain. Ionic manipulations used for
calibrating pH measurements can lead to exocytosis, confounding
interpretation of the data. To prevent exocytosis, we used flies
with the TeTxLC genetic background to generate a pH calibration
curve and found the baseline intraluminal pH of dopamine
vesicles in the fly brain to be B5.8, comparable to that reported
for mammalian synaptic vesicles (pH 5.7) (ref. 62). This value is
substantially more acidic than reported by Sturman et al.63
(pH 6.6) for synaptic vesicles in the fly neuromuscular junction.
This disparity could be due to differences in genetic backgrounds,
biosensors, sites of measurement and/or methods of calibration.
Given that the vesicular V-ATPase is the principal driver for
maintaining the acidic intraluminal pH and Hþ electrochemical
gradient (DpH), we propose that net vesicular alkalization occurs
if the rate of VMAT-mediated Hþ efflux exceeds the rate
of V-ATPase-mediated Hþ import. The rapid and reversible
alkalization induced by transient MPPþ pressure ejection
highlights the dynamic interplay of these opposing processes
within intact vesicles. We believe that this alkalization results
from elevated cytoplasmic pools of substrates driving VMAT-
mediated substrate:Hþ antiport at a sufficient rate to temporarily
outstrip the ability of the V-ATPase to maintain the original
acidic vesicular pH.
Our data lead to a model for how pharmacologically relevant
concentrations of amphetamines increase extracellular dopamine:
(1) DAT imports and concentrates amphetamines in the
cytoplasm. (2) Cytoplasmic amphetamines (and endogenous
dopamine) are accumulated into vesicles by VMAT in a Hþ -
antiport process that diminishes vesicular Hþ concentration.
(3) Diminished vesicular DpH promotes dopamine redistribution
from vesicles into the cytoplasm through a mechanism that is still
unclear. Vesicle deacidification alters the protonation state of
luminal dopamine, which might be sufficient to increase its
diffusion across the membrane. However, this mechanism does
not readily explain protonophore-induced efflux of MPPþ from
vesicles64, since this compound is a quaternary ammonium and
thus pH cannot alter MPPþ ’s protonation state. Whether VMAT
itself might be a route of dopamine release from vesicles11,65
requires further study. (4) The redistributed cytoplasmic
dopamine subsequently effluxes out of the cell through DAT
via amphetamine-stimulated reverse transport. Our previous
work demonstrated that phosphorylation of DAT is essential for
dopamine efflux66 and for locomotor behaviour induced by
amphetamine but not for the actions of methylphenidate, a
competitive non-substrate inhibitor of DAT20,21. These results
are consistent with the inference from our rodent behavioural
data that competitive inhibition at DAT by amphetamines is not
sufficient to produce behavioural effects at the concentrations
tested. By the same logic, stimulation of dopamine synthesis by
TH and/or inhibition of dopamine catabolism by monoamine
oxidases, both of which can elevate cytoplasmic dopamine
concentrations6, are insufficient in themselves to produce
amphetamines’ acute behavioural effects. These data highlight
the functional coupling of DAT and VMAT as critical to
amphetamines’ actions in vivo. Because amphetamines are
also substrates of norepinephrine transporter and serotonin
transporter, and VMAT is present in adrenergic and serotonergic
neurons6, the tandem actions of plasma membrane transporters
and VMAT are likely important for amphetamine-induced
release of other monoamines as well. Furthermore, our results
demonstrate the first application of a novel experimental system
that can be used to develop important new insights into the
physiology of intact monoaminergic vesicles.
Methods
Fly strains. D. melanogaster strains include the WT strain, w1118CS10 (wCS10),
which is w1118 outcrossed into Canton-S for 10 generations68. The dDAT null
fumin mutant dDATfmn (gift of K. Kume, Kumamoto University)38, dVMAT null
dVMAT1P1 69 and UAS-dVMAT transgene corresponding to the neuron-specific
dVMAT-A isoform have been previously described38,68,69. GAL4 expression driver
lines include TH-GAL4 (a gift of Dr S. Birman, Universite´ Aix-Marseille II-III)22
and Tdc2-GAL424 which were previously shown to drive expression in DA and
TA/OA neurons, respectively22,24. To detect pH changes in the intravesicular
lumen of monoaminergic synaptic vesicles, we constructed a new fly strain with the
novel transgene, UAS-dVMAT-pHluorin in both WT dDAT and dDATfmn genetic
backgrounds. All fly strains were grown and maintained on standard cornmeal-
molasses media at 25 C under a 12-h light–dark schedule.
Construction of transgenic fly strains. The dVMAT-pHluorin fly strain was
created by injection of the dVMAT-pHluorin probe sequence into WT fly embryos.
The probe was generated by insertion of the pH-sensitive, super-ecliptic pHluorin
DNA into the first luminal loop of dVMAT-A and surrounded by 50 linker
YPYDVPGSTSGGSGGTGG and 30 linker SGGTGGSGGTGGSGGTGYAT
between Arg-182 and Pro-183 of dVMAT-A. dVMAT-pHluorin was subsequently
genetically recombined with the TH-GAL4 expression driver on chromosome III.
This allowed us to achieve improved probe expression in the resulting homozygous
fly strain compared with the initial description of the probe18.
dVMAT rescue fly strains were constructed by introducing the UAS-dVMAT
transgene into the dVMATP1 null genetic background to selectively rescue dVMAT
function in DA and OA/TA neurons using the TH-GAL4 and Tdc2-GAL4
expression drivers, respectively. The following genotypes were described in the text:
(1) ‘TH Rescue’: w ; dVMATP1; TH-GAL4, UAS-dVMAT and (2) ‘Tdc Rescue’:
w ; dVMATP1, Tdc2-GAL4; UAS-dVMAT. To examine dVMAT-pHluorin’s
vesicular localization, we expressed the UAS-dVMAT-pHluorin transgene driven by
the elav-GAL4 expression driver: elav-GAL4;;UAS-dVMAT-pHluorin. To test the
effects of the respective expression drivers alone in the dVMAT null background,
we used the following fly strains: (1) w ; dVMATP1; TH-GAL4 and (2) w ;
dVMATP1, Tdc2-GAL4. Fly strains including the UAS-dVMAT transgene and
dVMATP1 allele were also outcrossed for 10 generations into the wCS10 WT
genetic background. To test whether dVMAT-pHluorin itself is functional in vivo,
we expressed the UAS-dVMAT-pHluorin transgene driven by the Tdc2-GAL4
expression driver in the dVMAT null background using the w ; dVMATP1, Tdc2-
GAL4; UAS-dVMAT-pHluorin fly strain, eliminating the potential confound of
endogenous dVMAT expression.
Fly brain imaging. Drug treatments. All drugs were diluted in adult haemolymph-
like saline (AHL; 108mM NaCl, 5mM KCl, 2mM CaCl2, 8.2mM MgCl2, 1mM
NaH2PO4, 10mM sucrose, 5mM trehalose, 5mM HEPES, 4mM NaHCO3; pH 7.5,
265mOsm). In most experiments, drugs were applied by bath superfusion into a
flow chamber at room temperature (25 C). Fluorescence was typically measured
before treatment and after a 10min drug equilibration period (25 C). In some
experiments, drugs were also applied by air pressure ejection (0.1–10 s) duration
onto brains submerged in AHL as described earlier16. Drug was delivered to a
pulled glass pipet directed at the MB-MV1 region at a distance of B10 mm away
from the brain using Picospritzer II (Parker Hannifin Corporation, Cleveland,
OH). To examine FFN206-labelling of presynaptic DA nerve terminals, we
continuously superfused FFN206 (300 nM, 30min) and examined brain neuropil
by multiphoton laser scanning microscopy. To induce synaptic vesicle exocytosis or
alkalization, we treated brains with KCl (40mM, in AHL adjusted for ionic
osmolarity) or CQ (100 mM) solutions, respectively. In experiments measuring
destaining of FFN206 from TH Rescue brains, the brains were loaded to steady
state with 300 nM FFN206 and then treated with drug solutions also containing
300 nM FFN206. To inhibit dVMAT activity, we pretreated brains with either
reserpine or (þ )-CYY477 (1 mM, 10–20min) and imaged in the continuous
presence of the respective blocker. To test effects on vesicular pH, brains were
incubated with 0.1–700 mM amphetamine, methamphetamine, MPH, DA, FFN206,
MPPþ or 30-OHMPPþ in fly brains expressing dVMAT-pHluorin in presynaptic
DA neurons in either a WT dDAT or dDATfmn genetic background. In experiments
using DA, we pretreated brains with monoamine oxidase (MAO) inhibitors
pargyline and selegiline (10 mM, 10min).
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Imaging. An isolated, ex vivo whole adult fly brain preparation was obtained by
rapid removal and microdissection of the brain from decapitated flies as previously
described16. A significant advantage of this preparation is that following removal of
head cuticle and connective tissues, drugs are applied directly to brain tissue at
known concentrations. This whole-brain preparation was imaged with continuous
flow on an Ultima multiphoton laser scanning microscope (Prairie Technologies
Bruker Corp., Middleton, WI). Fluorescent emission was collected using a 460 nm/
50 nm FWHM bandpass emission filter for FFN206 and 525/50 nm FWHM
bandpass filter for dVMAT-pHluorin.
Compounds. The drugs used in the present study including their respective salt
and enantiomeric forms were as follows and purchased from Sigma-Aldrich (St
Louis, MO) unless indicated otherwise: D-amphetamine hemisulphate, D-
methamphetamine HCl, cocaine HCl (Merck, Whitehouse Station, NJ), methyl-
phenidate HCl (MPH), bafilomycin A1 (Santa Cruz Biotechnology, Dallas, TX), 3-
hydroxytyramine HCl (dopamine), 2-(N-morpholino)ethanesulfonic acid (MES),
1-methyl-4-phenylpyridinium iodide (MPPþ ), carbonyl cyanide 4-(tri-
fluoromethoxy)phenylhydrazone (FCCP), monensin A sodium salt (monensin),
nigericin sodium salt (nigericin), N-methyl-N-propargylbenzylamine hydro-
chloride (pargyline HCl), reserpine, R( )-N-a-dimethyl-N-2-propynyl-benze-
neethanamine hydrochloride (selegiline HCl), N-Methyl-N-propargyl-3-(2,4-
dichlorophenoxy)propylamine hydrochloride (clorgyline HCl), 2-Cyano-N,N-die-
thyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide (entacapone), chloroquine
diphosphate (CQ), (±)-tetrabenazine (TBZ), haloperidol, Ro4-1248, tetrodotoxin
(Tocris Bioscience, Ellisville, MO), D-tubocurarine chloride (Tocris Bioscience),
Triton X-100, digitonin (Santa Cruz Biotechnology), valinomycin, adenosine 50-
triphosphate magnesium salt (ATP), L-ascorbic acid, potassium sodium tartrate
tetrahydrate, bovine serum albumin (fraction V; EMD Millipore, Billerica, MA),
green food coloring dye (La Flor Products, Ridgewood, NY). [3H]dihydrote-
trabenazine, [3H]nisoxetine, [3H]citalopram and [3H]dopamine were obtained
from American Radiolabelled Chemicals (St Louis, MO), and [3H]WIN 35,428 was
obtained from PerkinElmer Life Sciences (Waltham, MA). FFN206 (synthesized in
the Department of Chemistry, Columbia University, New York, NY), 1-methyl-4-
(30-hydroxyphenyl)phenylpyridinium iodide (30-OHMPPþ ; synthesized in the
Dept. of Chemistry, Wichita State University, Wichita, KS) and (þ )trans-10-
desmethyltetrabenazine [(þ )-CYY477] (synthesized at the School of Pharmacy,
College of Medicine, National Taiwan University, Taipei, Taiwan).
Preparation of (þ )-CYY477. Preparation of (þ )-CYY477 is described in detail
in the Supplementary Information. Briefly, treatment of commercially available 7-
hydroxy-6-methoxy-3,4-dihydroisoquinoline with 2-acetyl-N,N,N,4-tetra-
methylpentan-1-aminium iodide salt in refluxing ethanol provided racemic trans-
10-desmethyltetrabenazine [(±)-CYY477] in 59% yield. Optical resolution of (±)-
CYY477 using (þ )-2,3-dibenzoyl tartaric acid ((þ )-DBT) in ethanol yielded
optically pure (þ )-CYY477 (ee499%) according to our modifications to
previously described methods70 (see Supplementary Note 1, Supplementary
Figs 10–13).
Assay of Dopamine Uptake by VMAT2. 293-rV2 cells, HEK293 cells stably
transfected with rat VMAT2, were obtained from Dr R.H. Edwards and have been
previously characterized by Adam et al. (2008) and by Hu et al.17,71_ENREF_68.
Cells were grown in DMEM in 10% fetal bovine serum, 100 units per ml penicillin,
100mgml 1 streptomycin (37 C, 5% CO2) in polystyrene plates to 85%
confluency. On the day of assay, confluent cells were first washed with PBS,
trypsinized, and washed in DMEM before being placed in Resuspension Buffer
(110mM L(þ )-K-Na-tartaric acid, 5mM MgCl2, 5mM D-glucose, 20mM
HEPES-K, pH 7.4) at 37 C. Cells were counted and resuspended at a concentration
of B100,000 cells per 250ml in Assay Buffer (Resuspension Buffer supplemented
with 5mM Mg-ATP, 1mM ascorbate, 0.2% bovine serum albumin, 10 mM
digitonin, 10 mM of the COMT inhibitor entacapone and 10 mM each of the MAO
inhibitors selegiline, clorgyline, and pargyline). 250 ml aliquots of cells were
preincubated (10min, 37 C) either with 25ml of the respective test compound in
Assay Buffer or with 25ml of buffer without compound. Test compounds were
dissolved in DMSO, which was always o0.1% final concentration in the assay;
digitonin was dissolved in 100% ethanol (0.1% final concentration). Thereafter,
25ml of [3H]dopamine (60 Cimmol 1) suspended in Assay Buffer was added to
the assay mixture at a final concentration of approximately 10 nM (300 ml final
volume). After incubation with [3H]dopamine (10min, 37 C ), the assay mixture
was diluted to 1.5ml with ice cold Wash Buffer (85mM NaCl, 85mM KCl, 5mM
MgCl2, 20mM HEPES-K, pH 7.4) and immediately vacuum-filtred with a Brandel
24 well manifold (Brandel Instruments) and captured on prewetted Whatman GF/
B filters. The filtres were rapidly washed twice with 1.5ml Wash Buffer and then
dissolved in Safety Solve Complete Counting Cocktail liquid scintillant (Research
Products International, Mt. Prospect, IL) and counted on a Packard Tri-Carb 2100
TR liquid scintillation analyzer (PerkinElmer, Hopkinton, MA) at an efficiency of
B31%. Nonspecific uptake was defined using 10 mM Ro4-1248 and typically
ranged from 1–2% of total accumulated counts (typically B10% of total counts
added). Assays were performed with conditions in duplicate or triplicate for
each sample. Data in each assay were normalized to the mean control (maximal)
uptake level within the respective assay without background subtraction, and
the data from three separate experiments were pooled and analysed using
GraphPad Prism (version 5.0, GraphPad Software, La Jolla, CA) with a four
parameter logistic model.
dVMAT-pHluorin characterization. For both immunolabeling and live imaging
experiments at the larval neuromuscular junction (segment A4, muscle 13), the
UAS-dVMAT-pHluorin transgene was expressed in Type Ib nerve terminals using
the elav-GAL4 expression driver. For immunolabeling, larval fillets were fixed in
4% paraformaldehyde. Immunolabeling was performed in PBS containing 0.1%
Triton X 100 detergent and 5% normal goat serum using either a monoclonal
antibody to GFP (1:500, Invitrogen Life Technologies, Carlsbad, CA) or rabbit
antiserum to Drosophila synaptotagmin 1 (1:500 dilution, gift of N. Reist, Colorado
State University) followed by the appropriate secondary antibodies (1:1,000 dilu-
tion) conjugated to either Alexa Fluor 488 or Alexa Fluor 555 (both from Jackson
ImmunoResearch Laboratories, West Grove, PA), respectively. Images represent
projected Z-series acquired via confocal imaging (1 mm/section). For stimulated
release experiments, third instar larvae were prepared in chilled calcium-free HL3.1
saline (70 NaCl, 5mM KCl, 4mM MgCl2, 10mM NaHCO3. 5mM trehalose,
115mM sucrose, 5mM HEPES, adjusted to pH 7.3272) and recordings made in
HL3.1 supplemented with 2mM CaCl2 and 7mM L-glutamic acid (with the latter
to inhibit muscle contractions). The stimulus (40Hz, 10V, 2 s) was applied using a
suction electrode in contact with the free nerve root and stimulation-induced
changes in dVMAT-pHluorin fluorescence were imaged at a rate of 20 images/s.
To characterize the pH response properties of dVMAT-pHluorin in DA nerve
terminals of fly brain, we treated with 40mM KCl to stimulate exocytic release of
the biosensor across a range of extracellular pH’s (pH 5.5–8.3) using a modified
version of AHL with equimolar substitution of KCl for NaCl. To estimate the
intraluminal pH of intact dopaminergic synaptic vesicles in intact brain, we
generated a pH calibration curve using dVMAT-pHluorin and a buffered cocktail
of ionophores comprised of 20 mM FCCP, 10 mM valinomycin, 10 mM nigericin as
well as 1 mM bafilomycin A1 and 0.1% Triton X-100(final concentrations)73 across
a range of pH’s (pH 5.5–8.0) to permeabilize the vesicles and thus equilibrate the
intraluminal vesicular pH with the respective extracellular pH. To prevent exocytic
release of vesicles in response to ionophore treatment, these experiments were
performed in flies co-expressing tetanus toxin light chain in the same dopamine
terminals. We generated a pH calibration curve by graphing pH versus DF/Finitial
where Finitial was obtained while superfusing AHL (pH 7.5) for 10min without the
ionophore cocktail. Points chosen for the calibration curve were 2min following
complete bath exchange with the respective cocktail and fitted with GraphPad
Prism with a logistic model (Hill coefficient¼ 1). For improved stability in these
experiments, AHL was modified to include 9mM HEPES (pH 6.5–8.3) or 9mM
MES (pH 5.0–6.0) and NaHCO3 was excluded.
To determine the fraction of dVMAT-pHluorin expressed on the cell surface,
we used previously described methods31,33. Specifically, we subjected whole,
ex vivobrain preparations expressing dVMAT-pHluorin in presynaptic DA nerve
terminals to a brief acid wash (100 s, 25 C, pH 5.5) to quench fluorescence from
cell surface-expressed biosensor, followed by recovery of fluorescence after wash-
out (25 C, pH 7.5). To confirm these values, we used complementary NH4Cl
alkalization (50mM, 25 C, pH 7.5, 60 s) to visualize the intracellular vesicular
dVMAT-pHluorin pool combined with KCl treatment (40mM, 25 C, pH 7.5, 60 s)
to visualize both intracellular and externalized cell surface dVMAT-pHluorin
fluorescence. Using the brief acid wash method, we found that the percentage of
dVMAT-pHluorin on the cell surface under basal conditions was 14.5%±2.5%,
comparable to 17.7%±5.4% determined with the complementary NH4Cl
alkalization method.
Imaging. An isolated, ex vivo whole adult fly brain preparation was obtained by
rapid removal and microdissection of the brain from decapitated flies as previously
described16. This whole brain preparation was placed in a recording chamber (JG-
23, Warner Instruments, Hamden, CT) with continuous flow of AHL. This
experimental system affords facile manipulation of drug concentrations. The
timing by which drug solutions equilibrated in the imaging chamber was
determined by flowing an auto-fluorescent green dye dissolved in PBS buffer (1:100
dilution) under conditions identical to those experimentally used to deliver drugs
to fly brains. Brain preparations were imaged on an Ultima multiphoton laser
scanning microscope (Prairie Technologies Bruker Corporation, Middleton, WI)
using either a 63 (0.9 numerical aperture (NA)) or a 20 (1.0 NA) water
immersion objective lens (Carl Zeiss Microscopy LLC, Thornwood, NY). The
illumination source was a Coherent Chameleon Vision II Ti: Sapphire laser
(Coherent, Inc., Santa Clara, CA) and we typically usedo5mWmean power at the
sample. Fluorescent emission was collected using a 460 nm/50 nm FWHM
bandpass emission filtre for FFN206 (lex¼ 820 nm) and 525/50 nm FWHM
bandpass filtre for dVMAT-pHluorin (lex¼ 920 nm). When measuring the effect
of FFN206 on dVMAT-pHluorin brightening, there was no cross-talk of the
FFN206 signal into the dVMAT-pHluorin 525 nm/50 nm imaging channel when
using lex¼ 920 nm. We tested for spectral bleed-through and found that even a
1,000 mM solution of FFN206 generated no detectable fluorescence when using
dVMAT-pHluorin excitation parameters (lex¼ 920 nm,B1.5mW mean power at
sample). R3846 multi-alkali photomultiplier-tube detectors (Hamamatsu
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Photonics, Middlesex, NJ) were used for both FFN206 and dVMAT-pHluorin
imaging. Data acquisition was performed with Prairie View software (version
4.0.29, Prairie Technologies Bruker Corporation, Middleton, WI).
Fixed larval fillet preparations were imaged on a Zeiss LSM5 Pascal Laser
Scanning confocal microscope equipped with a Zeiss 63 Neofluor, 1.3 NA oil
immersion objective lens. Live imaging of these larval fillets was conducted using a
Zeiss Axio Examiner Z1 microscope equipped with a cooled back-illuminated
electron multiplying CCD camera (Andor iXon3 897, Andor, South Windsor, CT)
and DG4 light source (Sutter Instrument, Novato, CA) with a GFP Brightline Filter
Set (Semrock, Rochester, NY) and Zeiss Achroplan 100 (1.0 NA) water-
immersion objective lens.
Image processing and analysis. For experiments involving FFN206 or VMAT-
pHluorin imaging in adult fly central brain, maximum-intensity z-projections were
generated and quantified using the Fiji/ImageJ image processing package (National
Institutes of Health, Bethesda, MD). Unless indicated otherwise, we normalized
changes in images’ fluorescence intensity by using a ratio of fluorescence intensity
change (DF, calculated as F Fbaseline) relative to the maximal fluorescence
intensity change (DFmax, calculated as F Fmax) based on treatment with chlor-
oquine (100 mM, 25 C), DF/DFmax. In calibrating dVMAT-pHluorin’s pH-
dependent fluorescence intensity changes in adult central brain, we normalized the
respective fluorescence values to a DFmax derived from 40mM KCl, pH 8.3.
dVMAT-pHluorin fluorescence intensity changes in larval fillet preparations
during electrical stimulation were expressed as DF/F, which was calculated as
(F Fbaseline)/Fbaseline where Fbaseline is the average of intensities 2 s before stimulus.
Maximal DF/F in this preparation was calculated as (Fpeak Fbaseline)/Fbaseline,
where Fpeak is the average of the 10 frames (0.5 s) acquired immediately following
cessation of stimulation.
For curve fittings, images were corrected for background fluorescence and
subsequently normalized to initial predrug treatment MB-MV1 fluorescence (Fi)
using a custom program written in MATLAB (version R2012b, Mathworks, Natick,
MA) and described in further detail elsewhere (Aguilar et al., in preparation). The
decay time constant (tdecay) and decay half-time (t1/2) for FFN206 destaining were
estimated using the least-squares method to fit fluorescence values to a single-
exponential function preceded by a plateau phase: F/Fi(t)¼ (Fi-Plateau) e( (t t0)/
tdecay)þPlateau where t1/2¼ tdecay ln2 and where F/Fi(t) is the normalized
fluorescence value as a function of time. Similarly, the time constant for decay of
dVMAT-pHluorin fluorescence following electrical stimulation was estimated by
fitting DF/F values to a single exponential function (using GraphPad Prism). The
time constant (Tau, or 1/k) was calculated using the equation Y¼ (Y0Yp)e kt
where Y0 represents the peak after the stimulus and Yp represents the asymptotic,
plateau value of Y at t¼N with k as the rate constant of decay. The decay was
represented as t1/2 as calculated from the derived curve.
The signal to noise ratio (SNR) for FFN206 fluorescent signal was calculated as
a ratio of the average FFN206 fluorescence in the MB-MV1 region to the standard
deviation of background fluorescence. The dVMAT-pHluorin SNR was calculated
as the ratio of the CQ-induced peak fluorescence to the s.d. of baseline fluorescence
pre-drug treatment in MB-MV1. The dynamic range of dVMAT-pHluorin
fluorescence intensity was calculated as a ratio of peak fluorescence intensity to
initial fluorescence in response to KCl stimulation. All data were graphed using
GraphPad Prism.
Larval locomotion assay. Two hundred flies (3:2, females:males) of the respective
genotype were placed in bottles filled with standard medium and permitted to lay
eggs with experiments commencing on the fourth day of egg-laying. twenty to 30
early third instar larvae (82- to 86-h old) per experimental group were washed with
distilled water and placed onto 70% yeast paste (vehicle treatment) or 70% yeast
paste in 60mM amphetamine (Sigma, St Louis, MO) for 1 h (18 C). Food coloring
was added to the yeast paste to ascertain whether the larvae fed on the provided
paste. Fed larvae were subsequently transferred onto 100-mm Petri dishes filled
with 1% agar dissolved in distilled water. Each dish containing a set of 1–3 larvae
was placed on a cool-operated, evenly illuminated fluorescent light box positioned
underneath a video camera (Dalsa PT-41-04M60, Teledyne, Dalsa, Waterloo,
Ontario, Canada), which captured a high-contrast video image of larval profiles
over a featureless background. Larvae were acclimated on the agar plate for 1min
followed by 1min of data acquisition in a designated behaviour room (23–25 C,
35–40% humidity). We used the Multi-Worm Tracker and Choreography software
packages (open source availability) to track and quantify larval movement.
Rodent behaviour. See Supplementary Methods
Statistical analyses. Statistical significance for the larval behavioural data were
determined by one-way analysis of variance (ANOVA; a¼ 0.05) with a post hoc
two-sided Dunnett t-test for pairwise comparisons; SPSS (version 18.0, IBM,
Armonk, NY) was used for all statistical analyses. The coefficient of determination
(R2) corresponded to fitting experimentally-derived FFN206 destaining curves to a
one phase exponential decay preceded by a plateau phase; all curve fittings were
plotted using GraphPad Prism. For analysis of drug effects on dVMAT-pHluorin
fluorescence, respective treatment conditions were compared to vehicle via one-
way ANOVA (a¼ 0.05) followed by Bonferroni post hoc tests to compare between-
group differences. For analysis of the rodent behavioural data, statistical sig-
nificance was assessed by one- or two-way repeated-measures ANOVA (a¼ 0.05)
followed by post hoc Bonferroni t-tests for all pairwise comparisons. IC50 values
were computed using a nonlinear, least-squares regression analysis using GraphPad
Prism. Affinities (Ki values) were calculated using the Cheng–Prusoff equation74.
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